The substantial Hepalink investment along with the Zenith Royalty Preferred Shares and the Chinese licensing and Hepalink rights of first refusal on US manufacturing are difficult negotiating points for Resverlogix to overcome. It is what it is - they had to get the trial done. I would think that if Pfizer, Merck or any iother BP are involved and they view epigenetic therapies as a developmental opportunity they will want full control and all of the IP.

On the other side Hepa may view this as their entree as a dominant BP player in the future world market - they already have a foot in the door.  The market may see us as Shanghied so to speak.

All the details need to be legally addressed and resolved before moving forward - an onerous task to say the least.

jmo

Chicagoest